Startup Pinnacle Medicines is developing peptide drugs with the same efficacy as biologic medicines and the dosing convenience of oral small molecules. The lead program of OrbiMed-incubated Pinnacle is on track to enter the clinic in asthma and chronic obstructive pulmonary disease.
Vivtex’s technology uses AI and high throughput screening to identify the combinations of drug ingredients that can deliver peptides through gastrointestinal tissue. Besides Novo Nordisk, the MIT spinout’s partners include Astellas Pharma, Equillium, and Orbis Medicines.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx.
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
FogPharma’s lead program is a peptide that blocks a difficult-to-drug pathway inside of cells. The new financing will go toward an ongoing Phase 1/2 study in advanced solid tumors and support development of pipeline programs for other elusive cancer targets.
Orbis Medicines is developing macrocyclic peptides that address a wider range of targets and can be taken as oral pills. Novo Holdings and Forbion are backing the startup, which is based on research from the scientific co-founder of peptide drug developer Bicycle Therapeutics.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Stealth is moving towards Phase 3 trials in primary mitochondrial myopathy – a common denominator in many mitochondrial diseases – with an emphasis on improving patients' quality of life.